ACER — Acer Therapeutics Share News
0.000.00%
Last trade - 00:00Acer Therapeutics down after FDA approval as retail traders 'sell the news'
U.S. FDA approves Acer Therapeutics' genetic disorder drug (updated)
U.S. FDA approves Acer Therapeutics' genetic disorder drug
Acer Therapeutics up on private placement at premium
Brief: Acer Therapeutics Announces $1.5M Private Placement
Brief: Acer Therapeutics Has Received Notice Of Delisting From Nasdaq
Acer Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Brief: Acer Therapeutics Reports Q3 2022 Financial Results
Brief: Acer Therapeutics Receives Notice Of Allowance Of Key US Patent Application
Brief: SWK Holdings Provides Portfolio Update
Brief: Acer Therapeutics And Relief Therapeutics Announce Receipt Of Notice Of Allowance Of US Patent Application Covering A Kit Comprising Phenylbutyrate And Sodium Benzoate
Brief: Acer Therapeutics Entered First Amendment To Credit Agreement
Acer Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Acer Therapeutics Reports Q2 2022 Results
U.S. STOCKS ON THE MOVE-Forza X1, GlobalFoundries, Avient
U.S. STOCKS ON THE MOVE-AirSculpt, Honest, Acer Therapeutics
Acer Therapeutics rises after gaining EU's 'orphan drug' tag
Brief: Relief Therapeutics, Acer Therapeutics Report EC Orphan Drug Tag For ACER-001
Brief: Acer Therapeutics And Relief Therapeutics Announce FDA Acceptance For Review Of NDA Resubmission For Treatment Of UCDS